Low urinary placental growth factor is a marker of pre-eclampsia

被引:54
作者
Aggarwal, PK
Jain, V
Sakhuja, V
Karumanchi, SA
Jha, V [1 ]
机构
[1] Postgrad Inst Med Educ & Res, Dept Nephrol, Chandigarh 160012, India
[2] Postgrad Inst Med Educ & Res, Dept Obstet & Gynecol, Chandigarh 160012, India
[3] Beth Israel Deaconess Med Ctr, Dept Med, Div Renal, Boston, MA 02215 USA
[4] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
pre-eclampsia; placental growth factor; urinary biomarker; diagnosis;
D O I
10.1038/sj.ki.5000075
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Recent reports of increased serum levels of soluble fms-like tyrosine kinase 1 (sFlt-1) and decreased levels of placental growth factor (PlGF) suggest the key role of angiogenic factors in development of pre-eclampsia. PlGF is excreted in urine, and reduced urinary level has been suggested as a marker of this condition as well as help in its prediction. We measured urinary PlGF and creatinine values in 69 pregnant women (35 with pre-eclampsia and 34 normotensive controls). Over 70% patients had severe pre-eclampsia. Compared to controls, the urinary PlGF and PlGF/creatinine levels were significantly reduced in women with pre-eclampsia. The hospital stay was longer and fetal outcomes poorer in this group. Three normotensive women who showed very low levels developed pre-eclampsia 2-6 weeks later. Reduced urinary PlGF level in a pregnant woman is a marker of pre-eclampsia. The value of reduced urinary PlGF levels in predicting pre-eclampsia in currently normotensive pregnant women needs to be evaluated. A simple predictive test is likely to be of value in the developing countries.
引用
收藏
页码:621 / 624
页数:4
相关论文
共 20 条
[1]   VASCULAR-PERMEABILITY FACTOR MESSENGER-RNA AND PROTEIN EXPRESSION IN HUMAN KIDNEY [J].
BROWN, LF ;
BERSE, B ;
TOGNAZZI, K ;
MANSEAU, EJ ;
VANDEWATER, L ;
SENGER, DR ;
DVORAK, HF ;
ROSEN, S .
KIDNEY INTERNATIONAL, 1992, 42 (06) :1457-1461
[2]   Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia [J].
Buhimschi, CS ;
Norwitz, ER ;
Funai, E ;
Richman, S ;
Guller, S ;
Lockwood, CJ ;
Buhimschi, IA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 192 (03) :734-741
[3]   A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation [J].
Clark, DE ;
Smith, SK ;
He, YL ;
Day, KA ;
Licence, DR ;
Corps, AN ;
Lammoglia, R ;
Charnock-Jones, DS .
BIOLOGY OF REPRODUCTION, 1998, 59 (06) :1540-1548
[4]   INHIBITION OF VASCULAR ENDOTHELIAL-CELL GROWTH-FACTOR ACTIVITY BY AN ENDOGENOUSLY ENCODED SOLUBLE RECEPTOR [J].
KENDALL, RL ;
THOMAS, KA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (22) :10705-10709
[5]   Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia [J].
Koga, K ;
Osuga, Y ;
Yoshino, O ;
Hirota, Y ;
Xie, RM ;
Hirata, T ;
Takeda, S ;
Yano, T ;
Tsutsumi, O ;
Taketani, Y .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (05) :2348-2351
[6]   Urinary placental growth factor and risk of preeclampsia [J].
Levine, RJ ;
Thadhani, R ;
Qian, C ;
Lam, C ;
Lim, KH ;
Yu, KF ;
Blink, AL ;
Sachs, BP ;
Epstein, FH ;
Sibai, BM ;
Sukhatme, VP ;
Karumanchi, SA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (01) :77-85
[7]   Circulating angiogenic factors and the risk of preeclampsia [J].
Levine, RJ ;
Maynard, SE ;
Qian, C ;
Lim, KH ;
England, LJ ;
Yu, KF ;
Schisterman, EF ;
Thadhani, R ;
Sachs, BP ;
Epstein, FH ;
Sibai, BM ;
Sukhatme, VP ;
Karumanchi, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (07) :672-683
[8]   Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfimction, hypertension, and proteinuria in preeclampsia [J].
Maynard, SE ;
Min, JY ;
Merchan, J ;
Lim, KH ;
Li, JY ;
Mondal, S ;
Libermann, TA ;
Morgan, LP ;
Sellke, FW ;
Stillman, IE ;
Epstein, FH ;
Sukhatme, VP ;
Karumanchi, SA .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (05) :649-658
[9]   Vascular endothelial growth factor (VEGF) and its receptors [J].
Neufeld, G ;
Cohen, T ;
Gengrinovitch, S ;
Poltorak, Z .
FASEB JOURNAL, 1999, 13 (01) :9-22
[10]  
*PREV MAT MORT NET, 1995, SOC SCI MED, V40, P657